The report "Cardiac Marker Testing Market by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031" is projected to reach USD 9.06 billion by 2031 at a CAGR of 10.3% during the forecast period.
Browse 457 market data Tables and 55 Figures spread through 372 Pages and in-depth TOC on "Cardiac Marker Testing Market, by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cardiac-marker-market-64885447.html
The cardiac marker testing market is expected to grow steadily in the future due to various factors, such as a growing incidence rate of heart diseases, a growing number of heart diagnostic tests in emergency and routine cases, and a focus on early and accurate disease detection in various medical facilities. The growing trend of using advanced diagnostic techniques in heart diseases, along with a growing number of diagnostic facilities, is expected to create a new scope of growth in the cardiac marker testing market in the future.
In the cardiac marker testing market, the reagents & kits segment accounted for the larger share within the product segment in 2026.
This market is segmented into reagents/kits and instruments. Factors that drive the growth of the reagents/kits segment include the growing demand for advanced diagnostic solutions, the growing incidence of cardiovascular diseases, and the need to obtain quick and accurate results. Moreover, the expansion of diagnostic labs and infrastructure, combined with the constant improvement in the quality of automated testing equipment, is also fueling the demand for cardiac marker testing instruments.
In the cardiac marker testing market, the point-of-care testing segment is projected to register the highest growth during the forecast period.
The end users of the cardiac marker testing market include diagnostic labs, academic institutes, and point-of-care testing. The point-of-care testing segment is witnessing a strong growth trend, and this can be attributed to a number of factors, such as the rising need to achieve quick results in emergency and critical care settings. The increasing incidence of CVD and the need to achieve quick decision-making in patient care settings have led to a number of healthcare providers adopting point-of-care testing solutions for cardiac testing. The increased emphasis on decentralized patient care and the need to improve patient outcomes through quick diagnosis also contribute to the growth of point-of-care testing solutions for cardiac markers.
North America dominated the cardiac marker testing market in 2026.
The cardiac marker testing market segments are classified into five regions: Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa. North America accounted for the highest market share in the cardiac marker testing market in 2025. The market in this region is growing due to its healthcare infrastructure, high incidence rate of cardiovascular diseases, and the increased number of diagnostic tests performed in this region. High demand for cardiac marker testing in this region is due to the presence of high-end diagnostic centers and hospitals, along with stringent regulatory conditions for diagnostic accuracy, quality, and early detection of diseases.
The major players operating in this market are Healthineers Siemens (Germany), Roche Hoffmann (Switzerland), Danaher (US), Laboratories Abbott (US), Thermo Scientific (US), BD (US), Bio-Rad (US), Revvity (US), DiaSorin SPA (Italy), and Quidel Corporation (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com